Observational studyInternal and emergency medicine2026
FIB-4, a surrogate marker of liver fibrosis, predicts mortality and adverse events after acute myocardial ınfarction.
Observational study in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- FIB-4 predicts coronary disease and early outcomes in unstable angina pectoris.Internal and emergency medicine · 2026Article
- Association of the fibrosis-4 index with prevalent diabetes among adults: a cross-sectional analysis of NHANES 2003-2018 and a Chinese hospital-based health examination population.Frontiers in endocrinology · 2026Article
- FIB-4 Index, Systemic Inflammation, and Troponin Trajectory After Endovascular Thrombectomy in Older Patients with Large-Vessel Occlusion Stroke.Clinical interventions in aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Fibrosis-4 (FIB-4) score is a simple, non-invasive index originally developed to assess liver fibrosis. Recently, it has gained attention as a potential prognostic marker in cardiovascular diseases. This study aimed to evaluate whether the FIB-4 score, independent of its role in liver assessment, can predict short-term mortality and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI) undergoing coronary angiography (CAG) in the emergency department (ED). In this prospective observational study, 1017 patients diagnosed with AMI and treated with CAG between May 1, 2023, and February 29, 2024, were included. Patients were stratified into three groups based on FIB-4 score: low (< 1.45), intermediate (1.45-3.25), and high (> 3.25). Clinical and laboratory data, HEART scores, angiographic findings, in-hospital and 30-day outcomes were compared across groups. Patients with FIB-4 > 3.25 exhibited significantly higher rates of ST-elevation myocardial infarction (60.2%), hypertension (64%), diabetes mellitus (47.5%), atrial fibrillation (11%), and ventricular tachycardia (2.1%) (all p < 0.01). In-hospital mortality (14.4%), 30-day mortality (19.9%), and MACE (24.8%) were significantly elevated in this group (p < 0.001). Multivariate analysis identified FIB-4 > 3.25 (OR 3.816; p = 0.001), HEART score (OR 1.161; p = 0.013), and hemoglobin (OR 0.873; p = 0.038) as independent predictors of mortality. ROC analysis revealed moderate discriminative performance for FIB-4 (AUC: 0.693) and HEART score (AUC: 0.766). Elevated FIB-4 scores are independently associated with increased short-term mortality and adverse cardiovascular outcomes in AMI patients undergoing CAG. Beyond its traditional role in liver disease, the FIB-4 score may serve as a practical, non-invasive biomarker for early cardiovascular risk stratification in patients presenting to the ED with acute myocardial infarction.
Indexed as
Identifiers
40828444What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.